04:47 AM EST, 01/13/2025 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus.

Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of 2025.

Pending confirmation of its human leukocyte antigen matching strategy, Caribou said it expects to launch a phase 3 trial for CB-010 in H2 2025.

Meanwhile, the company also expects to present dose escalation data from its cancer drug CB-011 in relapsed or refractory multiple myeloma in H1 2025.